FDA Permits Expanded Access for Investigational Pancreatic Cancer …
5 days ago · Today, the U.S. Food and Drug Administration is announcing that it issued a “safe to proceed” letter to Revolution Medicines, allowing the sponsor to initiate an expanded access …
FDA expands access to drug helping pancreatic cancer patients
5 days ago · Daraxonrasib is being approved for use under the FDA's expanded access program. Also called "compassionate use," this option allows patients with serious or terminal conditions to take ...
FDA Allows Expanded Access to Daraxonrasib for PDAC
5 days ago · Key Takeaways FDA granted rapid expanded access for daraxonrasib in previously treated metastatic PDAC, reflecting urgency and a streamlined pathway for early patient access in life …
FDA Permits Expanded Daraxonrasib Access in Previously Treated ...
5 days ago · The FDA issued a “safe to proceed” letter for an expanded access program for daraxonrasib in metastatic pancreatic ductal adenocarcinoma.
FDA Green Lights Expanded Access to Pancreatic Cancer Drug ...
2 days ago · Eligible patients in the expanded access program will be able to receive daraxonrasib from their healthcare provider
FDA Green Lights Expanded Access Protocol for Daraxonrasib in ...
4 days ago · Key Takeaways Expanded access for daraxonrasib in post-treatment metastatic PDAC was cleared within 48 hours, reflecting FDA willingness to accelerate availability for life-threatening …
F.D.A. Grants Early Access to Promising Drug for Pancreatic Cancer
5 days ago · Many patients and families have pleaded for daraxonrasib to be offered through expanded access, saying they do not have time to wait for the drug to win regulatory approval. The Trump...
First RAS Inhibitor Extends Survival in Previously Treated Metastatic ...
5 days ago · Today, the U.S. Food and Drug Administration (FDA) announced that it has issued a “safe to proceed” letter to Revolution Medicines, allowing the company to initiate an expanded access …
FDA OKs Daraxonrasib Pancreatic Cancer Preapproval Access
4 days ago · FDA authorizes an expanded access treatment protocol after the oral RAS(ON) inhibitor doubled survival for metastatic patients in a phase 3 trial.
Expanded access to daraxonrasib signals ‘dawn of a new era’ in ...
1 day ago · Please provide your email address to receive an email when new articles are posted on . The FDA authorized expanded access to daraxonrasib for patients with pretreated metastatic …